Michael V. Milburn

GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC.

DRUIDapp, Inc. engages in the development of a measuring performance impairment tool. The company was founded by Michael V. Milburn in 2016 and is headquartered in Cambridge, MA.

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA.

Metabolon, Inc. operates as a health technology company. It offers precision medicine, clinical diagnostic, and metabolomics services. The firm serves to the pharmaceutical, biotechnology, consumer product industries. The company was founded in 2000 and is headquartered in Morrisville, NC.

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.